Anthem Biosciences: revenue up 8.0% to ₹594 Cr, net profit up 22.0% to ₹212 Cr
Results · Finvezto · 3 Nov 2026 · Anthem Biosciences (ANTHEM)
Results ₹ Cr
| Latest quarter | ₹ Cr | QoQ | YoY |
|---|---|---|---|
| Revenue | 594 | - | +8.0% |
| Operating profit | 272 | - | +24.6% |
| Net profit | 212 | - | +22.0% |
| Operating margin | 45.7% | - | +6.1 pp |
| Net margin | 35.6% | - | +4.1 pp |
YoY is the company's own figure. QoQ shows where our quarterly series matches the filing.
Key points
- Anthem Biosciences reported consolidated revenue from operations of Rs 594.00 crore for the second quarter ended September 30, 2026, up 7.9% year-on-year, with EBITDA rising 24.1% to Rs 330.40 crore and profit after tax increasing 21.9% to Rs 211.50 crore. NSE filing
- Revenue was driven by the CRDMO segment delivering Rs 509.30 crore, while EBITDA margin reached 50.6% and PAT margin stood at 32.4%. NSE filing
- Revenue was ₹594 Cr, up 8.0% on a year earlier. Finvezto data
Other figures
- Total Revenues: ₹653 Cr (+9.1% YoY)
Links
NSE filing (PDF) · Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.